HK Stock Market Move | UNITED LAB (03933) rises nearly 4%, plans to repurchase shares with up to 200 million Hong Kong dollars, TUL321 capsules granted implied approval for clinical trials of new drugs in China.

United Lab (03933) rose nearly 4%, as of the time of writing, it rose 3.91%, to HKD 8.76, with a turnover of HKD 68.7594 million. On the news front, on June 11th, United Lab announced that it intends to exercise its power to repurchase ordinary shares of the company based on the general authorization granted by the company's shareholders at the annual general meeting to be held on June 25, 2025, with a maximum investment of HKD 200 million to repurchase shares on the open market at an appropriate time. The company will subsequently cancel the repurchased shares. On the same day, United Lab announced that TUL321 capsules, a class 1 innovative drug developed by its wholly-owned subsidiary, Zhuhai United Lab Co., Ltd., has received an implied permit for new drug clinical trials from the China National Medical Products Administration. TUL321 capsules have also received new drug clinical trial approval from the U.S. Food and Drug Administration (FDA) on April 28, 2026.